Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors: State of Art Past 20 Years

Tuberculosis is a disease with high level of incidence and mortality. Due to the problems associated current therapy, it necessary urgent develop new drugs for treatment. Dihydrofolate reductase (DHFR) recognized target action several drugs. The 3D structure Mycobacterium tuberculosis DHFR (MtDHFR) elucidates key amino acid residues responsible active site architecture formation structural basis ligand specificity compared human (hDHFR). This article aims offer view on state art about MtDHFR inhibitors developed in last twenty years. study demonstrates correlation between efficacy presence specific groups, such as diaminopyridimidine ring that binds enzyme similarity structures classic methotrexate. Herein, also reported recent efforts molecules non-traditional cores, which could be more selective effective against tuberculosis.